Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9;10(11):1370.
doi: 10.3390/antibiotics10111370.

Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis

Affiliations

Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis

Oliver Spiller-Boulter et al. Antibiotics (Basel). .

Abstract

Lefamulin is the first of the pleuromutilin class of antimicrobials to be available for therapeutic use in humans. Minimum inhibitory concentrations of lefamulin were determined by microbroth dilution for 90 characterised clinical isolates (25 Ureaplasma parvum, 25 Ureaplasma urealyticum, and 40 Mycoplasma hominis). All Mycoplasma hominis isolates possessed lefamulin MICs of ≤0.25 mg/L after 48 h (MIC50/90 of 0.06/0.12 mg/L), despite an inherent resistance to macrolides; while Ureaplasma isolates had MICs of ≤2 mg/L after 24 h (MIC50/90 of 0.25/1 mg/L), despite inherent resistance to clindamycin. Two U. urealyticum isolates with additional A2058G mutations of 23S rRNA, and one U. parvum isolate with a R66Q67 deletion (all of which had a combined resistance to macrolides and clindamycin) only showed a 2-fold increase in lefamulin MIC (1-2 mg/L) relative to macrolide-susceptible strains. Lefamulin could be an effective alternative antimicrobial for treating Ureaplasma spp. and Mycoplasma hominis infections irrespective of intrinsic or acquired resistance to macrolides, lincosamides, and ketolides. Based on this potent in vitro activity and the known good, rapid, and homogenous tissue penetration of female and male urogenital tissues and glands, further exploration of clinical efficacy of lefamulin for the treatment of Mycoplasma and Ureaplasma urogenital infections is warranted.

Keywords: Mycoplasma hominis; Ureaplasma spp.; lefamulin; pleuromutilin; susceptibility testing.

PubMed Disclaimer

Conflict of interest statement

Susanne Paukner is employed by Nabriva Therapeutics GmbH, which also supplied the lefamulin for these studies. Oliver Spiller-Boulter was supported by a summer studentship award from HealthFirst Consulting. The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Minimal inhibitory concentrations for U. urealyticum relative to U. parvum for (A) lefamulin, (B) erythromycin, (C) tetracycline, (D) levofloxacin, and (E) moxifloxainafter strains with 23S rRNA A2058G, L4 and L22 mutations have been removed (A,B), strains carrying the gene tet(M) have been removed (C), or strains carrying mutations in the quinolone resistance determining region of parC and gyrB have been removed (D,E). Mean and standard error of the mean are also shown, with unpaired t-test analysis.

References

    1. Rosenthal K.S., Tan M.J. In: Rapid Review Microbiology and Immunology. 3rd ed. Goljan E.F., editor. Mosby, Elsevier; Philadelphia, PA, USA: 2011.
    1. Rocha E.P.C., Blanchard A. Genomic Repeats, Genome Plasticity and the Dynamics of Mycoplasma Evolution. Nucleic Acids Res. 2002;30:2031–2042. doi: 10.1093/nar/30.9.2031. - DOI - PMC - PubMed
    1. Gautier-Bouchardon A.V. Antimicrobial Resistance in Mycoplasma Spp. Microbiol. Spectr. 2018;6:407. doi: 10.1128/microbiolspec.ARBA-0030-2018. - DOI - PMC - PubMed
    1. Gnanadurai R., Fifer H. Mycoplasma Genitalium: A Review. Microbiology. 2020;166:21–29. doi: 10.1099/mic.0.000830. - DOI - PubMed
    1. Horner P., Donders G., Cusini M., Gomberg M., Jensen J.S., Unemo M. Should We Be Testing for Urogenital Mycoplasma Hominis, Ureaplasma Parvum and Ureaplasma Urealyticum in Men and Women?—A Position Statement from the European STI Guidelines Editorial Board. J. Eur. Acad. Dermatol. Venereol. 2018;32:1845–1851. doi: 10.1111/jdv.15146. - DOI - PubMed

LinkOut - more resources